4//SEC Filing
Scott Christopher K. 4
Accession 0000898432-21-000770
CIK 0001325618other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 9:37 PM ET
Size
19.2 KB
Accession
0000898432-21-000770
Insider Transaction Report
Form 4
IRADIMED CORPIRMD
Transactions
- Tax Payment
Common Stock
2021-12-07$48.27/sh−620$29,927→ 31,340 total - Exercise/Conversion
Common Stock
2021-12-07+2,732→ 34,072 total - Tax Payment
Common Stock
2021-12-07$48.27/sh−1,076$51,939→ 32,996 total - Exercise/Conversion
Common Stock
2021-12-07+1,575→ 31,960 total - Award
Restricted Stock Units
2021-12-07+4,143→ 4,143 total→ Common Stock (4,143 underlying) - Exercise/Conversion
Restricted Stock Units
2021-12-07−1,575→ 1,575 total→ Common Stock (1,575 underlying) - Exercise/Conversion
Restricted Stock Units
2021-12-07−2,732→ 5,463 total→ Common Stock (2,731 underlying) - Award
Performance-Based Restricted Stock Units
2021-12-07+4,143→ 4,143 total→ Common Stock (4,143 underlying)
Footnotes (8)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.
- [F3]The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
- [F4]The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2021 through December 7, 2024.
- [F5]If the relative measure at December 7, 2024 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting will be double the nominal granted shares.
- [F6]Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.
- [F7]On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
- [F8]On December 7, 2020, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
Documents
Issuer
IRADIMED CORP
CIK 0001325618
Entity typeother
Related Parties
1- filerCIK 0001613803
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 9:37 PM ET
- Size
- 19.2 KB